FAKTOR OPTIONSSCHEIN - ASTRAZENECA ADR | Real-time Bid/Ask 12:13:12 24/06/2024 BST | ||
| 5.25 EUR / 5.34 EUR | +4.44% |
|
| Current month | +6.29% | ||
| 1 month | -1.55% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24/06/24 | 5.23 | +3.16% |
| 21/06/24 | 5.07 | -0.78% |
| 20/06/24 | 5.11 | -0.20% |
| 19/06/24 | 5.12 | -3.94% |
| 18/06/24 | 5.33 | -5.50% |
Delayed Quote Börse Stuttgart
Last update June 24, 2024 at 07:24 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | UBS |
| WKN | UM5LFV |
| ISIN | DE000UM5LFV0 |
| Date issued | 14/05/2024 |
| Strike | 65.73 $ |
| Maturity | Unlimited |
| Parity | 2.35 : 1 |
| Emission price | 5 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.09 € |
|---|---|
| Lowest since issue | 4.41 € |
| Spread | 0.09 € |
| Spread % | 1.71% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.5
USD
Average target price
174.4
USD
Spread / Average Target
+10.77%
- Stock Market
- Certificates
- Certificat
